LOGIN  |  REGISTER
Cue Biopharma
Compass Therapeutics

Sharecare to report first quarter fiscal 2024 financial results on Thursday, May 9

April 24, 2024 | Last Trade: US$0.72 0.0054 -0.75

ATLANTA, April 24, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that it will report first quarter fiscal 2024 financial results on Thursday, May 9, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. EDT on the same day.

Conference Call Details

The conference call can be accessed by dialing (833) 636-1352 for U.S. participants, or (412) 902-4148 for international participants, and asking to be joined into the Sharecare call; or via live audio webcast, available online at https://investors.sharecare.com

A webcast replay of the call will be available for on-demand listening at the same link and will remain available for approximately 90 days.

About Sharecare

Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

Media Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB